Abstract 3898: Preclinical evaluation of DM21, a next-generation maytansinoid payload with a stable peptide linker

Volume: 79, Pages: 3898 - 3898
Published: Jul 1, 2019
Abstract
Antibody drug conjugates (ADCs) are designed to target surface antigen(s) expressed at higher levels on cancer cells compared to normal cells. ADCs are internalized and the antibody component is subsequently degraded in catabolic vesicles to release cytotoxic metabolites that can kill the cell. Membrane permeable metabolites can also diffuse into and kill neighboring cells (also called bystander cells) via a mechanism known as bystander killing,...
Paper Details
Title
Abstract 3898: Preclinical evaluation of DM21, a next-generation maytansinoid payload with a stable peptide linker
Published Date
Jul 1, 2019
Volume
79
Pages
3898 - 3898
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.